Dr. Preston Chase reports

OPTIMI HEALTH TO HOST MDMA EDUCATIONAL QUALITY ASSURANCE WEBINAR FOR CLINICIANS AND PRACTITIONERS

Optimi Health Corp. will hold an informative webinar titled "Know Your Drug Candidate: Safeguarding Quality in Psychedelic Therapy." This event, scheduled for Tuesday, Feb. 13, 2024, at 2 p.m. PST, is a crucial opportunity for clinicians, scientists, researchers, therapists, pharmacists and regulators involved or interested in the GMP (good manufacturing practice) manufacturing of psychedelic drug substances.

The session will be hosted by Optimi Health chief science officer Dr. Preston A. Chase and director of quality commercial strategies Karina Lahnakoski. Both individuals, considered experts in their respective fields, currently lead the company's cutting-edge science and quality assurance divisions. The webinar aims to provide invaluable educational insights into the meticulous processes involved in ensuring the quality, safety and international supply of the company's psychedelic drug candidates.

"Professionals aiming for a thorough grasp of the importance and impact of maintaining rigorous standards in psychedelic drug manufacturing and formulation are urged to attend," stated Dr. Chase and Ms. Lahnakoski. "Our responsibility, extending from the laboratory to the patient, is to consistently achieve and uphold the utmost quality benchmark, gauged by accountability and trust. It is paramount for Optimi to showcase its leadership in the industry by highlighting unparalleled product quality and excellence, setting a standard for the world to witness."

On Dec. 12, 2023, Lykos, formerly known as the Multidisciplinary Association for Psychedelic Studies Public Benefit Corp., submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for MDMA-assisted therapy for PTSD. The FDA is expected to decide on the acceptance of the NDA by Feb. 12, 2024. If accepted, a decision regarding the approval of the application is expected to be made within a time frame of either six or 10 months.

This impending decision, as highlighted by Optimi chief executive officer Bill Ciprick, has the potential to reshape the industry landscape, presenting Optimi with a golden opportunity to showcase its preparedness in supplying globally validated GMP drug candidates.

Mr. Ciprick emphasizes: "Critical inquiries still exist regarding the safety, accessibility, cost and supply of drugs necessary to meet the expected demand. We want this webinar to serve as a trustworthy guide for practitioners involved in global research and regulated patient access programs, as well as to share insights into the rigorous GMP quality standards, safety protocols and production criteria crucial for ensuring exceptional patient care and optimal research outcomes."

About Optimi Health Corp.

Optimi Health an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as MDMA, natural GMP-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets.

We seek Safe Harbor.